Nikolai Mentuk/iStock via Getty Images Parsons Corporation ( PSN ) has been awarded a $22M contract amendment by the Los Angeles County Metropolitan Transportation Authority (Metro) to deliver comprehensive multimodal infrastructure improvements along the I-605 corridor. The amendment extends Parsons’ existing contract by 3.5 years and aligns with Metro’s Board-adopted Multimodal Highway Investmen...
Nikolai Mentuk/iStock via Getty Images Parsons Corporation ( PSN ) has been awarded a $22M contract amendment by the Los Angeles County Metropolitan Transportation Authority (Metro) to deliver comprehensive multimodal infrastructure improvements along the I-605 corridor. The amendment extends Parsons’ existing contract by 3.5 years and aligns with Metro’s Board-adopted Multimodal Highway Investment Objectives. The project managed in partnership with Caltrans and the Gateway Cities Corridor Council of Governments, aims to alleviate severe congestion, enhance safety, and reduce commute times. To modernize the corridor, Parsons will oversee, the integration of managed lanes on the I-605 freeway. Optimized connectivity between local streets and freeway ramps, and community-focused upgrades, including new bicycle lanes, improved sidewalks, and enhanced transit access. "For over 20 years, Parsons has long been a trusted partner to Metro and the people of Los Angeles , helping them navigate the state – and world – seamlessly," said Mark Fialkowski , president, Infrastructure North America for Parsons. More on Parsons Parsons: Still Not An Attractive Opportunity Parsons Corporation (PSN) Presents at Bank of America 33rd Annual Industrials, Transportation and Airlines Key Leaders Conference Transcript Parsons Corporation (PSN) Q1 2026 Earnings Call Transcript Parsons lands fourth GARDEM award of 2026, totaling $218M Parsons wins $28M U.S. Air Force defense contract
Rogerio Xavier wants to set some things straight. First off, he says, no one staged a coup to topple him from the hedge-fund firm, SPX Capital, he had built into one of the biggest and most powerful in Brazil over the past two decades. And no, there were never any punches thrown as he and his co-partners haggled over how to restructure the firm and buoy its funds’ suddenly faltering returns. All t...
Rogerio Xavier wants to set some things straight. First off, he says, no one staged a coup to topple him from the hedge-fund firm, SPX Capital, he had built into one of the biggest and most powerful in Brazil over the past two decades. And no, there were never any punches thrown as he and his co-partners haggled over how to restructure the firm and buoy its funds’ suddenly faltering returns. All that chatter rippling through Brazilian financial circles blows out of proportion the occasional heated conversation between him and the partners, he says. “Speaking forcefully at times is just part of our nature — we’re traders, not nuns,” he says. “The fact that there’s debate doesn’t mean people cross certain lines.” However things went down when the SPX board gathered that afternoon in early May, what’s clear is this: Xavier, the firm’s principal shareholder, has been relegated to managing a far smaller chunk of money after posting several years of lackluster returns; the aggressive overseas expansion he had orchestrated, with offices in posh London and Manhattan neighborhoods, is all but over; and Bruno Pandolfi , a partner since the firm’s founding, has taken over management of the bulk of clients’ money. That pool of cash has shrunk steadily in recent years — from a peak of over 80 billion reais ($16 billion) to some 49 billion reais — as the firm’s subpar returns drove clients away. Then in March, things suddenly got a lot worse. The market gyrations triggered by the Iran war upended some of the firm’s trades, and its flagship fund, Nimitz , racked up its worst ever monthly loss — 5.5%. As Xavier tells it, the idea of a shakeup that would put one trader clearly in charge had been marinating for a while, and he eventually came to appreciate it was necessary. “We’ve had three or four years of mediocre performance,” Xavier, 59, said in an interview in Manhattan last month. He was in town for a few meetings and had set up shop in the temporary offices the firm was using ...
A diagnosis of pancreatic cancer is one of the most feared things in medicine. The disease has the highest mortality rate of all cancers. In 2026, roughly 67,530 Americans will be diagnosed with the disease in the U.S., and more than 52,740 will die from it, according to statistics from the Hirshberg Foundation for Pancreatic Cancer Research. On May 31, Revolution Medicines (NASDAQ: RVMD) presente...
A diagnosis of pancreatic cancer is one of the most feared things in medicine. The disease has the highest mortality rate of all cancers. In 2026, roughly 67,530 Americans will be diagnosed with the disease in the U.S., and more than 52,740 will die from it, according to statistics from the Hirshberg Foundation for Pancreatic Cancer Research. On May 31, Revolution Medicines (NASDAQ: RVMD) presented its Phase 3 trial findings for daraxonrasib, showing that this therapy, compared to chemotherapy, cut the risk of death by about 60% and more than doubled survival for patients with advanced pancreatic cancer. It is the first time any drug has pushed median overall survival past the one-year threshold in a Phase 3 trial for metastatic pancreatic cancer . On hearing that news, oncologists at a conference gave Revolution a standing ovation. Continue reading
Elon Musk is set to make a virtual appearance at a technology event hosted by semiconductor equipment leader ASML on Thursday, where he is expected to discuss Terafab, his proposed large-scale semiconductor manufacturing project designed to supply chips for Tesla (NASDAQ:TSLA) and SpaceX (NASDAQ:SPCX). The appearance comes as investors await the pricing of SpaceX’s initial public offering, which i...
Elon Musk is set to make a virtual appearance at a technology event hosted by semiconductor equipment leader ASML on Thursday, where he is expected to discuss Terafab, his proposed large-scale semiconductor manufacturing project designed to supply chips for Tesla (NASDAQ:TSLA) and SpaceX (NASDAQ:SPCX). The appearance comes as investors await the pricing of SpaceX’s initial public offering, which is expected later on Thursday and could become the largest IPO ever completed.
SAP (NYSE:SAP) shares fell more than 4% after competitor Oracle (NYSE:ORCL) revealed fiscal 2027 capital expenditure plans that significantly exceeded analyst expectations, highlighting the escalating costs associated with competing in the artificial intelligence infrastructure market. Oracle’s shares dropped more than 10% in premarket trading on Thursday after the company announced it could spend...
SAP (NYSE:SAP) shares fell more than 4% after competitor Oracle (NYSE:ORCL) revealed fiscal 2027 capital expenditure plans that significantly exceeded analyst expectations, highlighting the escalating costs associated with competing in the artificial intelligence infrastructure market. Oracle’s shares dropped more than 10% in premarket trading on Thursday after the company announced it could spend as much as $95 billion on capital projects during fiscal 2027.